StockData
GE HealthCare Technologies Inc. logo

GE HealthCare Technologies Inc. (GEHC) KPIs and segments

GEHCNasdaqX-Ray Apparatus & Tubes & Related Irradiation ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 14/308% below fair value
$83.66+1.82 (+2.22%)

Close on Nov 18, 2026Market cap $37.83BP/E 17.6Yield 0.17%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của GE HealthCare Technologies · năm tài chính kết thúc December 31 (Calendar Fiscal Year; FY2025 ended December 31, 2025; Q3 2026 ended September 30, 2026)

Nhìn nhanh KPI của GE HealthCare Technologies: 48 chỉ số vận hành, trong đó có Total Company Book-to-Bill Ratio (times), Total Ending Backlog và Total Remaining Performance Obligations — RPO, lấy từ 111 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
AIS($M)
3,8733,7713,6493,493
Imaging($M)
2,2992,5522,3492,2042,1402,3932,2292,1712,0622,392
AVS($M)
1,3411,5251,3011,2891,2391,4391,2161,2491,2271,382
PDx($M)
846843770790749729632646625639599591
PCS($M)
793675704824731778753827779772747827
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1
Product($M)
3,6023,4163,3453,9063,3753,2633,1173,6213,2013,2073,0453,597
Service($M)
1,9111,8781,7861,7921,7691,7431,6601,6981,6621,6321,6051,609
AIS($M)
1,5641,5171,4311,387
Imaging($M)
757838786734787888842778724
AVS($M)
679786646652641771608638628
PDx($M)
428421364389365358338331313325304
PCS($M)
269181223286228271272322293292287
Product($M)
1,2291,1991,0621,3561,1051,1031,1541,3951,1681,1621,0781,329
Service($M)
995980915905885880858880857840823827
Remaining performance obligations (RPO)($M)
16,11316,11815,82815,72915,09615,30414,87914,56314,53114,313
Total Company Book-to-Bill Ratio (times)(×)2
1.031.151.071.061.061.071.091.091.041.061.031.05
Organic Orders Growth (% YoY)(%)
4.0%11.1%1.1%2.0%6.0%3.0%10.0%6.0%1.0%3.0%1.0%3.0%
Organic Orders Growth — Exact One-Decimal Series (% YoY)(%)
4.0%11.1%1.1%2.0%5.7%10.3%5.6%
Total Ending Backlog ($B)1
23.7023.9021.8021.8021.2021.3019.80
Total Backlog Year-over-Year Dollar Change ($B)
2.502.601.202.002.200.70
Total Remaining Performance Obligations — RPO ($M)($M)2
16,11316,11815,82815,72915,09615,30414,87914,49114,56314,53114,31314,655
Products Remaining Performance Obligations ($M)($M)
5,3525,1805,1405,0014,8994,8054,5994,7554,8084,6484,7424,930
Services Remaining Performance Obligations ($M)($M)
10,76110,93910,68810,72810,19710,50010,2809,7379,7569,8839,5709,725
Advanced Imaging & Solutions (AIS) Segment Revenue ($M)($M)9
3,8733,7713,6404,0773,6493,4933,3793,8333,4453,4193,289
Radiology Sub-Segment Revenue — MR, CT, Molecular Imaging, X-Ray & Women's Health ($M)($M)
2,4632,3882,2992,5522,3492,2042,1402,3932,2292,1712,0622,392
Procedural Guidance Sub-Segment Revenue — Interventional & Surgical Visualization ($M)($M)
772715719789662660641744647668651727
Specialized Ultrasound Sub-Segment Revenue ($M)($M)
639668622735638630598696569581576655
AIS Reported Revenue Growth (% YoY)(%)
6.1%7.9%7.7%6.4%5.9%2.2%2.7%
AIS Organic Revenue Growth (% YoY)(%)
4.5%5.0%1.8%4.9%4.7%1.4%4.1%
AIS Organic Revenue Base ($M)($M)
3,8143,6683,4404,0203,6083,4683,423
AIS Foreign Exchange Revenue Impact ($M)($M)
-841140564125-57
AIS Acquisitions & Divestitures Revenue Contribution ($M)($M)
68626010014
AIS Segment EBIT ($M)($M)4
593525479641512455460676518463422
AIS Cost of Sales ($M)($M)
2,3092,2542,2042,4522,2182,1061,9512,1731,9952,0041,936
AIS Operating & Other Segment Expenses ($M)($M)
972992957984920932968984932952931
AIS Total Segment Costs & Expenses ($M)($M)
3,2813,2463,1613,4363,1383,0392,9193,1572,9272,9562,867
AIS Segment Depreciation & Amortization ($M)($M)
6767727373757577828386
Patient Care Solutions (PCS) Segment Revenue ($M)($M)8
793675704825731778753827779772747827
Monitoring Solutions Sub-Segment Revenue — Patient Monitoring & Diagnostic Cardiology ($M)($M)
584503519577544578556574556538527595
Life Support Solutions Sub-Segment Revenue — Anesthesia, Respiratory & Maternal-Infant Care ($M)($M)
209172185247187200197253223235220232
PCS Reported Revenue Growth (% YoY)(%)
8.5%-13.3%-6.5%-0.3%-6.2%0.8%0.8%
PCS Organic Revenue Growth (% YoY)(%)
8.8%-13.5%-8.1%-1.1%-6.7%0.4%1.7%
PCS Organic Revenue Base ($M)($M)
795673692818727775760
PCS Foreign Exchange Revenue Impact ($M)($M)
-2212743-7
PCS Acquisitions & Divestitures Revenue Contribution ($M)($M)
0000000
PCS Segment EBIT ($M)($M)5
68-261074276048106827881107
PCS Segment EBIT Margin (%)(%)
8.6%-3.8%1.4%9.0%3.7%7.7%6.4%12.8%10.5%10.1%10.8%
PCS Cost of Sales ($M)($M)
524494481538503507481505486480460
PCS Operating & Other Segment Expenses ($M)($M)
200207213212201212224216211215206
PCS Total Segment Costs & Expenses ($M)($M)
725700694750703719705721697694666
PCS Segment Depreciation & Amortization ($M)($M)
1313131314131314131415
Pharmaceutical Diagnostics (PDx) Segment Revenue — Contrast Media & Molecular Imaging Agents ($M)($M)6
846843770790749729632646625639599591
PDx Reported Revenue Growth (% YoY)(%)
13.0%15.6%21.8%22.3%19.8%14.1%5.6%
PDx Organic Revenue Growth (% YoY)(%)
13.8%14.6%9.7%12.7%9.6%5.0%7.9%
PDx Organic Revenue Base ($M)($M)
852835693726683669646
PDx Foreign Exchange Revenue Impact ($M)($M)
-687613157-14
PDx Acquisitions & Divestitures Revenue Contribution ($M)($M)
0005151530
PDx Segment EBIT ($M)($M)5
253250197234220213205212193200178192
PDx Segment EBIT Margin (%)(%)
29.9%29.7%25.6%29.6%29.4%29.2%32.4%32.9%30.9%31.3%29.7%
PDx Cost of Sales ($M)($M)
418422406400384371294314312314295
PDx Operating & Other Segment Expenses ($M)($M)
174171167156145144133119120125126
PDx Total Segment Costs & Expenses ($M)($M)
593593573556529516428433432439421
PDx Segment Depreciation & Amortization ($M)($M)
2019201919171212121516
Other / HealthCare Financial Services Revenue ($M)($M)1
2618715613131591514
Other / Unallocated Corporate Segment EBIT Impact ($M)($M)
-1152212011-1-1
United States & Canada (USCAN) Region Revenue ($M)($M)1
2,6722,4762,3612,5972,3582,3402,2372,3992,2462,2092,1272,254
USCAN Reported Revenue Growth (% YoY)(%)
13.3%5.8%5.6%5.0%6.0%5.0%8.0%3.0%2.0%
Europe, Middle East & Africa (EMEA) Region Revenue ($M)($M)1
1,3541,3481,3401,6231,3601,2681,1741,4341,2371,2021,1791,425
EMEA Reported Revenue Growth (% YoY)(%)
-0.4%6.3%14.1%10.0%6.0%0.0%-1.0%-1.0%1.0%
China Region Revenue — Mainland China, Hong Kong, Macau & Taiwan ($M)($M)1
586582567547547563593615564584597680
China Region Reported Revenue Growth (% YoY)(%)
7.1%3.4%-4.4%-3.0%-4.0%-1.0%-22.0%-18.0%-11.0%
Rest of World Region Revenue — Asia-Pacific ex-China & Latin America ($M)($M)1
901888863931878836773872816845748847
Rest of World Reported Revenue Growth (% YoY)(%)
2.6%6.3%11.6%8.0%-1.0%3.0%5.0%13.0%-5.0%
Total Company Organic Revenue Growth (% YoY)(%)4
6.2%3.5%2.9%4.8%3.5%1.7%4.1%
Total Company Reported Revenue Growth (% YoY)(%)
7.2%5.7%7.4%7.1%5.8%3.5%2.7%
Total Company Organic Revenue Base ($M)($M)
5,4625,1824,9165,5715,0334,9174,842
Total Company Foreign Exchange Revenue Impact ($M)($M)
-1651155756036-78
Total Company Acquisitions & Divestitures Revenue Impact ($M)($M)
68626052515314
Total Contract & Other Deferred Assets ($M)($M)5
1,5771,4521,3641,2851,2871,1861,1441,1831,2211,1801,1361,168
Current Contract & Other Deferred Assets ($M)($M)
1,3651,2351,1591,0731,0699789539741,0339949611,000
Current Contract Assets — Unbilled Equipment & Service Milestones ($M)($M)
875776715645625542546589612582577600
Current Other Deferred Assets ($M)($M)
489459444428444436407385421412384400
Noncurrent Contract Assets ($M)($M)
8791849198928310390907872
Noncurrent Other Deferred Assets ($M)($M)
12612512212012011610810598969796
Total Contract Liabilities — Deferred Revenue ($M)($M)6
3,1473,0572,9722,8992,7772,7202,6132,6292,6192,5622,5662,623
Current Contract Liabilities ($M)($M)
2,2512,2002,1532,0952,0021,9791,8891,9431,9151,8761,8791,918
Noncurrent Contract Liabilities ($M)($M)
895857819803775741724686704685687705
Revenue Recognized from Beginning Contract Liability Balance ($M)($M)
280406783203251382752204265375741197
Current Customer Refund & Rebate Liabilities ($M)($M)
14110387148118133151153135126136144
Current Sales Allowances & Related Liabilities ($M)($M)
258237225256228228221242215211208228
Noncurrent Sales Allowances & Related Liabilities ($M)($M)
292625232327242323232427
Total Inventories, Net of Reserves ($M)($M)4
2,6282,4832,3532,2342,3042,2832,1581,9392,1242,0231,9891,960
Raw Materials & Component Inventories ($M)($M)
1,1451,0631,0801,0021,0111,026991921992934927961
Work in Process Inventories ($M)($M)
1181031049510193999210010210191
Finished Goods & Service Parts Inventories ($M)($M)
1,3651,3171,1701,1371,1911,1641,0689261,032987961908
Noncurrent Inventories ($M)($M)
143127122121140145143139151149154147
Current Customer & Other Receivables, Net ($M)($M)6
3,9253,8813,7863,9553,7343,5623,5723,566
Gross Current Trade Customer Receivables ($M)($M)
3,6093,5353,4653,7193,4743,3373,3793,382
Allowance for Credit Losses on Current Receivables ($M)($M)
10110210010310810710610310410310298
Current Non-Trade & Other Receivables ($M)($M)
257279247180198165144133
Current Value-Added Tax (VAT) Receivables ($M)($M)
160169174159170167155155
Noncurrent Financing & Customer Receivables, Net ($M)($M)
170183187190189191161142167153130124
Confirmed Supplier Finance Program Obligations Outstanding ($M)($M)
354334341360344346364394403393384365
Product Warranty Liability Balance ($M)($M)3
178176161169160166171168168172175192
Current Product Warranty Liability ($M)($M)
178176161169160166171168168172175192
New Product Warranties Issued / Accrued ($M)($M)
496143583754595947554158
Product Warranty Claims Paid / Settled ($M)($M)
484550514362585454575559
Restructuring Reserve Liability Balance ($M)($M)7
99109111928976898680767668
Restructuring Reserve — Workforce Severance ($M)($M)
95103103827863736743
Restructuring Reserve — Facility Exit & Site Closures ($M)($M)
478111113161825
Restructuring & Asset Impairment Charges Recognized ($M)($M)
172749493118223022294020
Employee Severance & Related Restructuring Expense ($M)($M)
162544383012212419172512
Facility Exit & Contract Termination Expense ($M)($M)
023511032581
Cash Payments for Restructuring Actions ($M)($M)
25262537172517
Expected Remaining Cost of Approved Restructuring Programs ($M)($M)
213825532434403621162520
Property, Plant & Equipment, Gross ($M)($M)5
5,9685,7995,6935,7315,8925,8415,6615,2675,3565,2075,1805,208
Machinery, Manufacturing & Test Equipment, Gross ($M)($M)
2,9382,8722,8142,8722,9952,9752,9052,7052,617
Buildings, Structures & Related Equipment, Gross ($M)($M)
2,2552,2072,1552,1402,1912,1992,1071,9431,956
Leasehold Improvements & Manufacturing Plant Installations, Gross ($M)($M)
633582582574556516503553565
Land & Land Improvements, Gross ($M)($M)
1421391421441501521466670
Operating Lease Expense ($M)($M)
596063-49636062-55705960-46
Adjusted EBIT ($M)($M)3
913750691950761729715994795742681837
Adjusted EBIT Margin (%)(%)
16.6%14.2%13.5%16.7%14.8%14.6%15.0%18.7%16.3%15.3%14.7%16.1%
Amortization of Acquisition-Related Intangible Assets ($M)($M)
616147404140353734353132
Acquisition & Disposition Related Costs / Benefits ($M)($M)
-11-11-35-15-9-7-8-104300
Adjusted Net Income ($M)($M)2
609514452659490487464667525461414541
GAAP Net Income Margin (%)(%)
11.1%10.6%7.6%10.3%8.7%9.7%11.8%13.5%9.7%8.8%8.0%7.7%
Adjusted Diluted Earnings Per Share ($/share)($)
1.341.130.991.441.071.061.011.451.1410.901.18
Free Cash Flow — Non-GAAP ($M)($M)
79345135916483798811651-182274956
Redeemable Noncontrolling Interest Carrying Balance — Joint Ventures ($M)($M)3
234229218209204220211188177177177165
Net Income Attributable to Noncontrolling Interests ($M)($M)
9132213181424171971413
Cash Paid for Business Acquisitions, Net of Cash Acquired ($M)($M)
0-42,2979901026954025900
Goodwill Added from Business Acquisitions ($M)($M)
39451,5845829-221641019500
FDA 510(k) Premarket Clearances Granted to GE HealthCare5
9412567643748
U.S. MedTech Industry Total FDA 510(k) Clearances Granted
855923756806797886736856767793713877
FDA Premarket Approval (PMA) Decisions & Supplements — GE HealthCare
000100100000
U.S. MedTech Industry Total FDA PMA Decisions & Supplements
565608567525585588524683538550459656
FDA Device Recall Events Posted — GE HealthCare
1625103130224324341485
FDA Device Enforcement Reports — GE HealthCare
17259313225382736987
FDA MAUDE Medical Device Reports (MDRs) Received — GE HealthCare Total4
7928608899441,2881,586684772664642651524
FDA MAUDE Device Malfunction Reports — GE HealthCare
7798458569261,2781,562659753647633638502
FDA MAUDE Serious Injury Reports — GE HealthCare
1015321792221181691221
FDA MAUDE Death Reports — GE HealthCare
001112201010
U.S. MedTech Industry Total FDA MAUDE Adverse Event Reports
1,189,467923,529811,618751,012819,444632,296685,251709,498699,798631,546586,309573,619
Cumulative ClinicalTrials.gov Studies Sponsored by GE HealthCare1
New Clinical Studies Initiated by GE HealthCare
755345623534
U.S. Federal Government Prime Contract Obligations Awarded to GE HealthCare ($M)($M)
7.9612.41.954.7214.730.83.404.0321.80.2110.65.10
U.S. Industrial Production Index: Medical Equipment & Supplies (NAICS 3391, Index 2017=100)2
U.S. Producer Price Index: Surgical & Medical Instruments (Index)(×)
163.40162.90161.70159.60157.80156.90157.10155.20154.40154.10153.60151.00
U.S. CPI: Medical Care Services (Index 1982–84=100)(×)
654.70650.90647.60638.40630.60623.40619.60613.00611.40605.80597.90
Total Consolidated Revenues ($M)($M)
5,5135,2955,1315,6985,1435,0074,7775,3194,8634,8394,6505,206
Consolidated Gross Profit ($M)($M)2
2,2242,1801,9772,2611,9901,9852,0122,2752,0262,0021,9022,156
Cost of Products ($M)($M)
2,3732,2172,2832,5502,2702,1601,9632,2262,0332,0451,9672,268
Cost of Services ($M)($M)
916898871887884863802818805792782782
Consolidated Operating Income ($M)($M)8
805739515827653654629801676608540689
Research & Development Expense ($M)($M)
320323345323292302344344316327324315
Selling, General & Administrative Expense ($M)($M)
1,1001,1181,1171,1111,0451,0291,0401,1301,0341,0671,0381,152
Total Operating Expenses ($M)($M)
1,4191,4411,4621,4341,3371,3311,3831,4741,3501,3951,3621,467
Income Before Income Taxes ($M)($M)
752693505821643613692834658578512609
Provision for Income Taxes ($M)($M)
1291199421917911310496168143124193
Net Income Attributable to GE HealthCare ($M)($M)
615561389589446486564721470428374403
GAAP Diluted Earnings Per Share ($/share)($)
1.361.240.851.290.981.061.231.571.020.930.810.88
Weighted-Average Diluted Shares Outstanding (Millions)(M)
453454457045745845904594594590
Total Assets ($M)($M)6
38,37137,24637,12536,90636,12735,50033,58633,08933,85531,85232,20832,454
Cash, Cash Equivalents & Restricted Cash ($M)($M)
2,8262,0792,2614,4924,0303,7662,4762,8933,5722,0182,5652,506
Total Current Assets ($M)($M)
11,49510,49710,42612,50111,89311,3089,7359,90110,6388,8069,3739,410
Property, Plant & Equipment, Net ($M)($M)
3,2193,1463,0953,0923,0102,9622,8512,5502,5392,4582,4452,144
Goodwill ($M)($M)
15,14015,09515,06013,48913,44113,41713,37313,13613,13813,11612,92712,936
Other Intangible Assets, Net ($M)($M)
1,8121,8941,9081,1301,1631,2201,2381,0781,1321,1951,1741,253
Operating Lease Right-of-Use Assets ($M)($M)
383391396410409386369364359359354356
Total Liabilities ($M)($M)7
26,50826,02726,22726,30725,90725,54824,16824,43725,34323,85824,60925,144
Total Current Liabilities ($M)($M)
8,8158,3028,5299,10510,0739,7489,9699,5538,6708,3188,8598,981
Accounts Payable ($M)($M)
3,3203,2313,4103,2502,9872,9753,1523,0352,9112,8242,9312,947
Short-Term Borrowings & Current Portion of Long-Term Debt ($M)($M)
3275082,0052,0052,0021,5021,0071,0071,0081,006
Long-Term Borrowings ($M)($M)
9,97010,09110,1279,4958,2778,2706,7577,4499,3068,2338,2478,436
Total Operating Lease Liabilities ($M)($M)
382394402419419398386385378380376383
Noncurrent Pension & Postretirement Benefit Liabilities ($M)($M)
5,1075,1865,3005,4535,2875,3515,4435,5835,3885,4555,6255,782
Total Stockholders' Equity Attributable to GE HealthCare ($M)($M)
11,61410,97510,66810,3799,9939,7129,1878,4468,3177,8017,4087,133
Cash Flows from Operating Activities ($M)($M)8
9071682901,05059394250913742-1194191,050
Additions to Property, Plant & Equipment and Internal-Use Software ($M)($M)
11410017813411086152102906414594
Share-Based Compensation Expense ($M)($M)
364535363834223322363433
Cash Dividends Paid to Stockholders ($M)($M)
161616161616161413141413
Common Stock Dividends Declared Per Share ($/share)($)
0.040.040.040.040.0700.040.040.030.030.030.03
Cash Income Taxes Paid, Net ($M)($M)
7013992768317991116882018699
Cash Interest Paid ($M)($M)
841938719567182782116521955252
Cash Flows from Investing Activities ($M)($M)
-111-115-2,500-269-148-223-407-240-137-349-188-88
Cash Flows from Financing Activities ($M)($M)
-40-23621-293-1651,361-286-1,277914-57-153-900

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Core Commercial & Operational Drivers (Groups 1–3): Total Company Book-to-Bill Ratio (x), Organic Orders Growth (% YoY), Total Ending Backlog ($B) and YoY Backlog Dollar Change ($B), Remaining Performance Obligations (RPO $M split between Products and Services), granular product sub-segment revenues (Radiology, Procedural Guidance, Specialized Ultrasound, Monitoring Solutions, Life Support Solutions, and PDx) continuously reconciled across the October 2024 (AVS) and July 2026 (AIS) Form 8-K recast filings, and four-region customer revenues (USCAN, EMEA, China region, and Rest of World).
  • Parent-Only vs. Consolidated Financial Statements: GE HealthCare Technologies Inc. files under U.S. GAAP (Form 10-K / Form 10-Q) without separate parent-company-only Schedule I financial statements because restricted net assets of consolidated subsidiaries do not exceed 25% of consolidated net assets. Subsidiary and joint venture operations are captured directly from explicit disclosures in Group 7 (Exhibit 21.1 subsidiary counts by jurisdiction, redeemable noncontrolling interest balances and net income, M&A cash deployment, and UK statutory filings for GE Healthcare Limited and GE Medical Systems Limited).
  • Derived Period Splitting: Quarterly values for fourth-quarter geographic revenues, segment cost disaggregation, and cash flow / footnote rollforward items reported on a cumulative year-to-date basis in Form 10-Q and Form 10-K are derived strictly via Q2 = 6M − Q1, Q3 = 9M − 6M, and Q4 = FY − 9M.

Không hiện vì thiếu các kỳ gần đây (20)

  • Orders, Book-to-Bill, Backlog & Remaining Performance Obligations (Core Commercial Drivers) › Total Remaining Performance Obligations — RPO ($M) › Products Remaining Performance Obligations ($M) › Products RPO Expected to Be Recognized Within 2 Years (%)
  • Orders, Book-to-Bill, Backlog & Remaining Performance Obligations (Core Commercial Drivers) › Total Remaining Performance Obligations — RPO ($M) › Services Remaining Performance Obligations ($M) › Services RPO Expected to Be Recognized Within 2 Years (%)
  • Orders, Book-to-Bill, Backlog & Remaining Performance Obligations (Core Commercial Drivers) › Total Remaining Performance Obligations — RPO ($M) › Services Remaining Performance Obligations ($M) › Services RPO Expected to Be Recognized Within 5 Years (%)
  • Sub-Segment & Segment Operations (Radiology, Procedural Guidance, Specialized Ultrasound, PDx & PCS) › Advanced Imaging & Solutions (AIS) Segment Revenue ($M) › AIS Segment EBIT ($M) › AIS Segment EBIT Margin (%)
  • Sub-Segment & Segment Operations (Radiology, Procedural Guidance, Specialized Ultrasound, PDx & PCS) › Legacy Segment Structure — Advanced Visualization Solutions (AVS) Revenue ($M, Prior to Q2 2026 AIS Realignment) › Legacy AVS Segment EBIT ($M, Prior to Q2 2026 AIS Realignment)
  • Sub-Segment & Segment Operations (Radiology, Procedural Guidance, Specialized Ultrasound, PDx & PCS) › Legacy Segment Structure — Advanced Visualization Solutions (AVS) Revenue ($M, Prior to Q2 2026 AIS Realignment) › Legacy Imaging Segment EBIT ($M, Prior to Q2 2026 AIS Realignment)
  • Sub-Segment & Segment Operations (Radiology, Procedural Guidance, Specialized Ultrasound, PDx & PCS) › Legacy Segment Structure — Advanced Visualization Solutions (AVS) Revenue ($M, Prior to Q2 2026 AIS Realignment)
  • Workforce, Commercial, R&D & Manufacturing Footprint, Supply Chain & Governance (10-K, Form SD, DEF 14A) › Total Global Employees / Colleagues › United States Employees
  • Workforce, Commercial, R&D & Manufacturing Footprint, Supply Chain & Governance (10-K, Form SD, DEF 14A) › Total Global Employees / Colleagues › China Region Employees
  • Workforce, Commercial, R&D & Manufacturing Footprint, Supply Chain & Governance (10-K, Form SD, DEF 14A) › Total Global Employees / Colleagues › U.S. Union-Represented Manufacturing Employees
  • Contract Assets & Liabilities, Working Capital, Warranty, Restructuring & Lease Footnotes (Note 2 & XBRL) › Property, Plant & Equipment, Gross ($M) › Unrecorded Unconditional Purchase Obligations — Total Committed ($M)
  • Contract Assets & Liabilities, Working Capital, Warranty, Restructuring & Lease Footnotes (Note 2 & XBRL) › Property, Plant & Equipment, Gross ($M) › Unconditional Purchase Obligations Due Within 1 Year ($M)
  • Global Installed Base (over 4 million / over 5 million imaging, mobile diagnostics, and monitoring units globally) — Disclosed only as a lower-bound figure ('over 4 million' / 'more than 5 million') rather than an exact point count.
  • Segment Installed Base Approximations (~400,000 Imaging systems and ~400,000 Ultrasound systems) — Disclosed only once in the 2022 Form 10-12B/A Spin-Off Information Statement without multi-year updates.
  • Customers Served in Over 160 Countries and Approximately 1 Billion Patients Served Annually — Disclosed only as lower-bound marketing approximations ('over 160 countries', 'approximately 1 billion patients').
  • AI-Enabled Device Authorizations (over 100 / 115+ FDA 510(k) AI-enabled clearances) — Disclosed only as cumulative lower-bound milestones in promotional highlights; exact period-by-period 510(k) clearances are captured directly from the U.S. FDA openFDA database.
  • Recurring Revenue Share of Total Revenue (more than 45% in FY2024) — Disclosed only as a lower-bound percentage ('more than 45%') on the Q4 2024 earnings call.
  • The Spirit & The Letter Code of Conduct Training Completion for FY2025 (>99.9%) — FY2025 value disclosed as a lower bound ('>99.9%'), leaving only FY2022–FY2024 point values without the latest completed fiscal year.
  • Total Facility Waste Generated, Hazardous Waste, and Non-Hazardous Waste Recycling Breakdown (40,966 mt total, 2,701 mt hazardous, 38,265 mt non-hazardous in FY2025) — First disclosed in the 2025 Sustainability Report with only 1 year (FY2025) of history.
  • Employee Engagement Survey Completion and Glint Engagement Score (75% in FY2023, 64%/75% in FY2024, pulse survey in FY2025) — Discontinued annual full-population survey format in FY2025 in favor of random pulse surveys.

Dữ liệu cập nhật 2026-11-07.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Non-GAAP Profitability, Free Cash Flow Conversion & Special Items Reconciliations

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của GE HealthCare Technologies

See a number that looks wrong?